trending Market Intelligence /marketintelligence/en/news-insights/trending/klabiqj7muzt3h6xyrzfsw2 content esgSubNav
In This List

Celgene scalp psoriasis therapy meets main goal in late-stage study

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Celgene scalp psoriasis therapy meets main goal in late-stage study

SNL Image

Celgene Corp.'s Otezla met its main goal in a late-stage study in patients with scalp psoriasis, a type of skin disease.

Under the phase 3 trial, Otezla, when administered twice daily, achieved a highly statistically significant improvement in patients with moderate to severe scalp psoriasis at week 16 compared to placebo. The therapy's effect was measured by the Scalp Physician's Global Assessment response score.

Otezla, or apremilast, also significantly eased itching over the whole body for patients under the trial compared to those receiving placebo, as measured by the whole-body itch numeric scale.

The therapy's safety under the 303-patient study, called Style, was generally consistent with Otezla's known safety profile. Side effects from the treatment include diarrhea, nausea, headache and vomiting.

Psoriasis is a chronic and systemic inflammatory disorder which affects 125 million people worldwide.

Otezla is already approved to treat patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Summit, N.J.-based Celgene is evaluating the drug as a potential treatment of active ulcerative colitis, a chronic, relapsing inflammatory bowel disease, and Behcet's disease, a rare, chronic multisystem inflammatory syndrome.